Navigation path


Development of novel management strategies for invasive aspergillosis
EC contribution
: € 2.914.800
: 36 months
Starting date
: 01/01/2007
Funding scheme
: Specific Targeted Research Project
: immunotherapy, vaccine, antigens, T-cells, dendritic cells, A. fumigatus, PCR diagnostics, monoclonal antibodies, GMP-conditions, aspergillosis, transplantation
Contract/Grant agreement number
: LSHM-CT-2006-037899
Project web-site


The overall objective of the MANASP project was to develop new treatment strategies for Invasive Aspergillosis (IA) - the major infectious complication of treating haematological malignancies with intensive chemotherapy or haematopoietic stem cell transplantation (HSCT).

Ineffective host immune responses facilitate fungal invasion of the pulmonary system and other vital organs leading to death. In order to redress this immunological imbalance we propose to develop new immunotherapeutic strategies which will augment current antifungal treatments and reduce morbidity and mortality.

Facilitated by recent publication of the A. fumigatus (the principal pathogen of the genus) genome sequence we will exploit new knowledge and techniques in genomics and post-genomics. We will identify the immunologically important fungal molecules to design immunotherapies based on vaccines using fungus-primed innate immune cells, monoclonal antibodies or adoptive transfer of specific T lymphocyte clones.

We will also generate new nucleic acid based diagnostic tests to inform when and how immunotherapy can be optimally applied.
The outcomes will have strong commercial applications which will be delivered by three leading European SMEs within the consortium.

[+] Read More